- Details
- Following presentations at the ASCO 2020 Virtual Annual Meeting, Toni Chouieri, MD, discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma. The phase II OMNIVORE study enrolled patients with advanced RCC and no prior checkpoint inhibit...
|
- Details
- PDIGREE is a novel adaptive frontline immunotherapy study which upon completion will help answer many important questions regarding treatment duration, when to combine VEGF therapy with IO therapy, and which patients benefit most from IO-VEGF combination upfront vs. sequential therapy. This trial is actively enrolling patients at all National Clinical Trials Network (NCTN) study sites. The primary...
|
- Details
- Clear cell renal carcinoma has a modest tumor mutational burden and increased infiltration of CD8+ T cells which is associated with worse prognosis in this disease. Biomarkers for response to immune checkpoint inhibitors are needed to predict which patients will respond. David Braun joins Alicia Morgans and overviews his ASCO 2020 presentation on the genomic and immune determinants of response to...
|
- Details
- It is unknown what the optimal duration of nivolumab maintenance is to sustain disease control and what the response rate to single-agent nivolumab is for treatment naïve patients with metastatic renal cell carcinoma (mRCC). OMNIVORE a response-based phase II study seeks to help answer some of these questions. This study enrolled patients with treatment-naïve or previously treated advanced RCC (aR...
|
- Details
- Brian Rini joins Charles Ryan to discuss frontline therapy in kidney cancer, specifically focusing on the recent updates on the combination of axitinib and pembrolizumab in the Keynote-426 data. KEYNOTE-426 study, which is at the two-year mark of followup, is a randomized, open-label, phase 3 study that demonstrated that pembrolizumab (pembro) + axitinib (axi) significantly improved overall surviv...
|
- Details
- In this episode of Kidney Cancer Today, Bradley McGregor joins Monty Pal and Jamie Landman to speak about the major practice-changing studies that have come out over the past year in the frontline setting and the evolution of therapy in the renal cell carcinoma space. Biographies: Bradley McGregor, MD, Clinical Director, Senior Physician, Instructor in Medicine, Lank Center for Genitourinary Oncol...
|
- Details
- Rana McKay and Monty Pal share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation. Biographies: Rana R. McKay, MD, Medical Oncologist, Assistant Professor of Medicine, UC San Diego Health Sumanta Kumar Pal, MD Associate Clinical Profe...
|
- Details
- In this episode of Kidney Cancer Today, Jaimie Landman helps Monty Pal dissect some of the biggest issues on active surveillance for renal cell carcinoma. The following questions were discussed. Who is the right patient for active surveillance? Can a T1b patient be a candidate for active surveillance? What are the best clinical practices post five years after resection in the surveillance setting?...
|
- Details
- Shaan Dudani joins Monty Pal and Jaime Landman, sharing an overview of the First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium which was published this past August in European urology. Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patient...
|
- Details
- Alicia Morgans and David Braun discuss his innovative research in metastatic kidney cancer which focuses on understanding and improving immunotherapies in kidney cancer. His work utilizes immunogenomic approaches to generate mechanisms of response and resistance to existing immunotherapies. He is working to develop novel immune-based treatments. David’s key talking points are driven from the thoug...
|
